^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD123 positive

    i
    Other names: IL3RA, Interleukin 3 receptor subunit alpha, CD123, Interleukin 3 Receptor Alpha, IL-3 Receptor Subunit Alpha, IL-3R Subunit Alpha, CD123 Antigen, IL-3R-Alpha, IL-3RA , IL3R, IL-3 Receptor Alpha SP2 Isoform
    Entrez ID:
    3563
    Related biomarkers:
    Expression
    Others
    Apply
    IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia (IMGN632-0802) (NCT04086264)
    Phase 1/2
    AbbVie
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/06/2019
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    IL3RA
    |
    CD123 positive • IL3RA positive
    |
    Venclexta (venetoclax) • azacitidine • decitabine • Decnupaz (pivekimab sunirine-pvzy)
    Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (NCT04230265)
    Phase 1
    AvenCell Europe GmbH
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    01/28/2020
    Primary completion :
    05/01/2025
    Completion :
    09/01/2025
    IL3RA
    |
    CD123 positive
    |
    cyclophosphamide • fludarabine IV • AVC-101
    A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure (NCI-2022-02215) (NCT05285813)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    05/06/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    IL3RA
    |
    CD123 positive • CD123 expression • IL3RA expression
    |
    vibecotamab (XmAb14045)
    Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents (TAGALONG) (NCT05442216)
    Phase 2
    Joshua Zeidner
    Recruiting
    Last update posted :
    05/02/2024
    Initiation :
    05/01/2024
    Primary completion :
    08/01/2027
    Completion :
    12/01/2027
    IL3RA
    |
    CD123 positive
    |
    Venclexta (venetoclax) • azacitidine • Elzonris (tagraxofusp-erzs)
    First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT05817058)
    Phase 1
    Affimed GmbH
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    03/21/2023
    Primary completion :
    03/01/2025
    Completion :
    03/01/2026
    IL3RA
    |
    CD123 positive • IL3RA positive
    |
    AFM28
    Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia (NCT05720988)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Withdrawn
    Last update posted :
    03/08/2024
    Initiation :
    08/03/2024
    Primary completion :
    08/03/2025
    Completion :
    08/03/2026
    CD123 • IL3RA
    |
    CD123 positive • CD123 expression • IL3RA expression
    |
    azacitidine • Elzonris (tagraxofusp-erzs)
    Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm (NCI-2014-01147) (NCT02159495)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/30/2024
    Initiation :
    12/15/2015
    Primary completion :
    12/15/2024
    Completion :
    12/15/2024
    FLT3 • CD123 • IL3RA
    |
    CD123 positive
    |
    cyclophosphamide • fludarabine IV • CD123R(EQ)28zeta/EGFRt+ T cells • cyclophosphamide intravenous • MB-102
    Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (NCT05032183)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    10/16/2023
    Initiation :
    02/17/2022
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    IL3RA
    |
    CD123 positive
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Truxima (rituximab-abbs) • Elzonris (tagraxofusp-erzs) • mercaptopurine • mesna • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
    A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat (NCT05320380)
    Phase 1/2
    Children's Oncology Group
    Withdrawn
    Last update posted :
    09/01/2023
    Initiation :
    08/01/2023
    Primary completion :
    09/01/2023
    Completion :
    09/01/2023
    IL3RA
    |
    CD123 positive • IL3RA positive
    |
    methotrexate • Vyxeos (cytarabine/daunorubicin liposomal formulation) • fludarabine IV • Decnupaz (pivekimab sunirine-pvzy) • Starasid (cytarabine ocfosfate)
    Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm (NCT06006403)
    Phase 1/2
    Chongqing Precision Biotech Co., Ltd
    Recruiting
    Last update posted :
    08/30/2023
    Initiation :
    08/31/2023
    Primary completion :
    12/31/2025
    Completion :
    08/31/2026
    IL6 • CD123 • IL3RA
    |
    CD123 positive • CD123 expression • IL3RA positive
    |
    cyclophosphamide • CD123 targeted CAR-NK
    Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN (CADENZA) (NCT03386513)
    Phase 1/2
    ImmunoGen, Inc.
    Active, not recruiting
    Last update posted :
    08/03/2023
    Initiation :
    01/02/2018
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    IL3RA
    |
    CD123 positive • CD123 expression • IL3RA expression
    |
    Decnupaz (pivekimab sunirine-pvzy)
    Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia (NCT05574608)
    Phase 1
    Affiliated Hospital to Academy of Military Medi...
    Recruiting
    Last update posted :
    04/26/2023
    Initiation :
    10/01/2022
    Primary completion :
    10/30/2023
    Completion :
    10/30/2024
    CD123 • IL3RA
    |
    CD123 positive
    |
    JD023